Non-Invasive Eosinophilic Gastritis Diagnostic
Non-Invasive Eosinophilic Gastritis Diagnostic
Technology Overview
Diagnostic assay to monitor or diagnose Eosinophilic Gastritis (EG) through detection of the presence and level of biomarkers in the blood of a patient. The use of a blood assay reduces the need of tissue biopsy of the esophagus while screening, diagnosing, monitoring Eosinophilic Esophagitis (EoE). This technology offers an opportunity to diagnose and monitor EoE through blood testing instead of sedation and esophageal biopsy. The blood biomarker testing allows monitoring of the disease and status without the need to visualize and biopsy through an invasive procedure. These advantages include improved accuracy, earlier diagnosis, better monitoring, and more effective treatment.
Applications
Diagnostic assay to monitor or diagnose Eosinophilic Gastritis (EG) through detection of the presence and level of biomarkers in the blood of a patient. The use of a blood assay reduces the need of tissue biopsy of the esophagus while screening, diagnosing, monitoring Eosinophilic Esophagitis (EoE)
Advantages
This technology offers an opportunity to diagnose and monitor EoE through blood testing instead of sedation and esophageal biopsy. The blood biomarker testing allows monitoring of the disease and status without the need to visualize and biopsy through an invasive procedure. These advantages include improved accuracy, earlier diagnosis, better monitoring, and more effective treatment.
Market Overview
Prevalence of EOE in the US is approximately 57-90 / 100K people. Slightly lower in the European market at 30-50 / 100K. The Incidence is 5-10 / 100K people.
Investigator Overview
Dr. Mark Rothenberg Dr. Tetsuo Shoda
Technology ID
2019-0211
Complementary Technology
2020-0206
Business Opportunity
Exclusive License
Technology Type
Diagnostic
Stage of Development
Pre-Clinical - Human
Patent Information
US Non-Provisional Filing